## Multi-resistant fungi from various human and animal sources

Paul E. Verweij, MD FECMM Centre of Expertise in Mycology Radboudumc/CWZ National Institute for Public Health and the Environment February 2020

#### **Disclosures**






## Fungi are everywhere!

-00


S

## The fungal environment: 6 million species!?






#### **Acquired fungal resistance: the suspects**




## Aspergillus and its habitat











## **Pathogenesis invasive aspergillosis**




## Change?

## Influenza-associated aspergillosis



#### Am J Respir Crit Care Med. 2017;196:524-527







#### Am J Respir Crit Care Med. 2017;196:524-527

## Fungi are eukaryotes just like humans.....











## Azoles are the main drug class for management of IA




## **Impact of resistance**



Radboudumc

0%

Azole



Lack of sensitive diagnostic tools for early resistance detection



Lack of alternative drugs with similar efficacy



## **Clinical implications?**

Radboudumc – LUMC – ErasmusMC

2011 - 2015


All patients with A. fumigatus in culture

All isolates screened with VIPcheck<sup>™</sup>

**Compare mortality in R versus S** 


#### 196 patients with invasive aspergillosis

#### **Voriconazole resistance phenotype**




P. Lestrade et al. Clin Infect Dis 2019;68:1463–1471.

#### 196 patients with invasive aspergillosis




#### P. Lestrade et al. Clin Infect Dis 2019;68:1463–1471.




#### P. Lestrade et al. Clin Infect Dis 2019;68:1463–1471.

#### Putting azole-resistant associated 12-week mortality of IA in perspective





## Activity of antifungal agents: azole resistance



## How are patients with resistant IA infected?

Disease	Route of resistance	Comments	
CF	E > P		
ABPA	?		
Aspergilloma	P >> E	azole therapy, cavity, multiple R- mutations, fitness cost	
CPA	P >> E	azole therapy, cavity, multiple R- mutations, fitness cost	
IA - pulmonary	E	2/3 no azole therapy, TR <sub>34</sub> > TR <sub>46</sub> , mixed infections	
IAA	Ε	TR <sub>34</sub> > TR <sub>46</sub> , mixed infections, tracheobronchitis	
CNS-IA	E	TR <sub>34</sub> &TR <sub>46</sub> , sanctuary site	

P = patient route E = environmental route


## How are patients with resistant IA infected?



Propiconazole; tebuconazole; epoxiconazole; difenoconazole; bromuconazole







#### Medical triazoles






#### Radboudumc

#### Lancet Infect Dis. 2009;9:789-95


#### **Mixed infections**








#### Resistance diagnosis and appropriateness of antifungal therapy



Clin Infect Dis 2019;68:1463–1471.

## Management strategy.....New SWAB guideline



December 2017

#### Multidisciplinary mycology team



#### Center of Expertise in Mycology Radboudumc/CWZ

### Acquired resistance frequency in A. fumigatus 2013 - 2017



**5 university medical centers** 

Screening for resistance of unselected clinical isolates using VIPcheck<sup>™</sup>

Includes clinically not-relevant isolates


Number of patients screened 600 to 814 per annum

number of patients with azoleR isolate

number of screened patients


#### www.swab.nl: Netmap 2019:128-31

#### **Anticipated risk: Aspergillus resistance surveillance**



80% to 90% environmental

#### **Acquired resistance: global?**




Clin Microbiol Infect. 2019;25:799-806.


## Do you worry about AMR?

An antibiotic is an antimicrobial drug used to treat bacterial infections in humans and animals.

Like humans, animals (including farm animals) carry bacteria. when antibiotics are given to animals, the drugs kill most of the bacteria, but resistant bacteria can survive and multiply.



#### Figure 2.6 Antibiotic use and AMR from 1990–2000 in selected countries



#### DDD: Defined Daily Doses

Total antibiotic use in outpatients versus prevalence of penicillin-nonsusceptible *Streptococcus pneumoniae* in 20 industrialized countries.

# $AMR \neq ABR$

## Funding of infectious disease projects by ZonMw – last 14 years!

Program	Period	Budget (M€)	Molds included?	No projects awarded	No fungal projects
Infectieziektebestrijding	2006 - 2011	12.6	Tolerated	33	1
Q-koorts	2010-2014	3	No	14	0
Infectieziektebestrijding	2014 - 2017	17	Fungal resistance excluded		
Ronde 1 (Non-alimentaire zoönosen)				6	0
Ronde 2				14	0
Ronde 3 (Non-alimentaire zoönosen)				9	0
Ronde 4				9	0
Priority Medicines Antimicrobiële Resistentie	2009 - 2018	14.76	Fungi excluded	28	0
Antibioticaresistentie	2016 - 2023	16	Fungi excluded		
Ronde 1				10	0
Ronde 2				6	0
Totaal		63.36		129	1 (0.8%)

#### Medisch Contact April 2018


# Azole resistance in A. fumigatus: Under the radar......



## **CDC** – antibiotic resistance threats

#### ANTIBIOTIC RESISTANCE THREATS IN THE UNITED STATES

2019





#### LINN' VI LIN

#### **Urgent Threats**

- Carbapenem-resistant Acinetobacter
- Candida auris (C. auris)
- Clostridioides difficile (C. difficile)
- Carbapenem-resistant Enterobacteriaceae (CRE)
- Drug-resistant *Neisseria gonorrhoeae (N. gonorrhoeae)*

#### **Serious Threats**

- Drug-resistant Campylobacter
- Drug-resistant Candida
- Extended-spectrum beta-lactamase (ESBL)-producing Enterol, cteriaceae
- Vancomycin-resistant Enterococci (VRE)
- Multidrug-resistant Pseudomonas aeruginosa (P. aeruginosa)
- Drug-resistant nontyphoidal Salmonella
- Drug-resistant Salmonella serotype Typhi
- Drug-resistant Shigella
- Methicillin-resistant Staphylococcus aureus (MRSA)
- Drug-resistant *Streptococcus pneumoniae* (S. pneumoniae)
- Drug-resistant Tuberculosis (TB)

#### **Concerning Threats**

- Erythromycin-resistant group A Streptococcus
- Clindamycin-resistant group B Streptococcus


#### Watch List

- Azole-resistant Aspergillus fumigatus (A. fumigatus)
- Drug-resistant Mycoplasma genitalium (M. genitalium)
- Drug-resistant Bordetella pertussis (B. pertussis)



#### November 2019

## The environment: Deadly flower power?



### Clin Infect Dis. 2017;65:147-149

A. fumigatus is able to complete its life cycle



presence of azole residues

# Flower bulb waste Green waste Wood chippings waste Strawberry waste

Emerg Infect Dis. 2019;25:1347-1353

# **Azole fungicide residues in hotspots**



40 samples analyzed – 34 contained azole fungicide residues (85%)

Median of 2.5 compounds per sample – range 1 to 8

11 different azole fungicide compounds and 3 metabolites

tebuconazole (24 samples) prothioconazole (13) epoxiconazole (11) azaconazole (8) propiconazole (7)

Median concentration 0.036 mg/l (range 0.01 mg/l to 6.4 mg/l)

Each gram of compost contained >1x10<sup>6</sup> A. fumigatus spores

# Where?




## application of fungicides



## collection of organic waste






mature compost

Emerg Infect Dis. 2019;25:1347-1353

# **Commercial composting**





#### Emerg Infect Dis. 2019;25:1347-1353

# Where?




## application of fungicides



## collection of organic waste








mature compost

## How are patients infected? – potential sources



# How are patients infected? – potential sources



tea







onions

carrots

## How are patients infected? – water?



Threat?	yes	Develop better diagnostic tests New drug targets
<b>Global?</b>	yes	Set up international surveillance Include fungal resistance in One- health programs
Forgotten?	yes	Prioritize fungal resistance research Include fungal resistance in AMR initiatives